Hostname: page-component-78c5997874-v9fdk Total loading time: 0 Render date: 2024-11-15T01:22:02.840Z Has data issue: false hasContentIssue false
  • English
  • Français

Global health challenges in the pharmaceutical world

Published online by Cambridge University Press:  22 December 2008

JOHN ABRAHAM
JOHN ABRAHAM*
Affiliation:
Professor of Sociology and Director of the Centre for Research in Health and Medicine (CRHaM), University of Sussex, UK
*
* Correspondence to: Professor John Abraham. Centre for Research in Health and Medicine (CRHaM), Department of Sociology, School of Social & Cultural Studies, University of Sussex, Falmer, Brighton BN1 9SN, UK. Email: J.W.Abraham@sussex.ac.uk
Get access Rights & Permissions [Opens in a new window]

Abstract

An abstract is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Review Essay
Information
Health Economics, Policy and Law , Volume 4 , Issue 1 , January 2009 , pp. 115 - 127
Copyright
Copyright © Cambridge University Press 2009

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Abraham, J. (1995), Science, Politics and the Pharmaceutical Industry, London/New York: UCL/St Martins Press.Google Scholar
Abraham, J. and Davis, C.(2005), ‘A comparative analysis of drug safety withdrawals in the UK and the US (1971–1992): implications for current regulatory thinking’, Social Science and Medicine, 61: 881–892.CrossRefGoogle ScholarPubMed
Abraham, J. and Davis, C.(2007), ‘Interpellative sociology of pharmaceuticals: problems and challenges for innovation and regulation in the twenty-first century’, Technology Analysis and Strategic Management, 19: 387–402.CrossRefGoogle Scholar
Abraham, J. and Reed, T. (2001), ‘Trading risks for markets: the international harmonization of pharmaceuticals regulation’, Health, Risk and Society, 3: 113–128.CrossRefGoogle Scholar
Abraham, J. and Sheppard, J.(1999), The Therapeutic Nightmare: The Battle over the World’s most Controversial Sleeping Pill, London: Earthscan.Google Scholar
Alaszewski, A. (ed.) (2001), Risk, Health and Globalization (Special Issue of Health, Risk and Society), 3(1):5–128.Google Scholar
Daemmrich, A.A.(2004), Pharmacopolitics: Drug Regulation in the United States and Germany, Chapel Hill: University of North Carolina Press.Google Scholar
Healy, D. (2004), Let Them Eat Prozac, New York and London: New York University Press.Google Scholar
Hilts, P.J. (2003), Protecting America’s Health: The FDA, Business and One Hundred Years of Regulation, New York: Knopf.Google Scholar
House of Commons Health Committee (2005), The Influence of the Pharmaceutical Industry, Fourth Report of Session 2004–05, Volume 1, London: TSO.Google Scholar
Lazarou, J., Pomeranz, B.H.and Corey, P.N. (1998), ‘Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies’, Journal of the American Medical Association, 279: 1200–1205.CrossRefGoogle ScholarPubMed
Lofgren, H. (ed.) (2004), Regulating Health: Global Pharmaceuticals in Transition (Special Issue of Australian Health Review), 28(2): 147–205.Google Scholar
Medawar, C. (1992), Power and Dependence: Social Audit on the Safety of Medicines, London: Social Audit.Google Scholar
Medawar, C. and Hardon, A.(2004), Medicines out of Control? Antidepressants and the Conspiracy of Goodwill, The Netherlands: Askant Academic Publishers.Google Scholar
Mossialos, E., Mrazek, M., and Walley, T. (2004), Regulating Pharmaceuticals in Europe, Maidenhead: Open University Press.Google Scholar
Sklair, L. (2001), The Transnational Capitalist Class, Oxford: Blackwell.Google Scholar